Nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)

Abstract

A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof.

1 - 10 . (canceled) 
     
     
         11 . A method of modulating LH pulsatility in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of 3-(methanesulfonamido)-2-phenyl-N-[(1 S)-1-phenylpropyl]quinoline-4-carboxamide (NK3RA): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         12 . A method of treating polycystic ovarian syndrome in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide (NK3RA): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         13 . The method according to  claim 12  wherein the method is a method of treating amenorrhea, oligomenorrhea, or anovulation in polycystic ovarian syndrome. 
     
     
         14 . The method according to  claim 11  wherein the method is a method of restorating fertility. 
     
     
         15 . (canceled) 
     
     
         16 . A method of treating PCOS comprising the step of determining whether the testosterone level of a biological sample taken from a patient is higher than the normal level and, if it is, treating said patient with a therapeutically effective amount of 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide (NK3RA): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         17 . A method according to any one of  claims 11 - 14  or  16  wherein 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide (NK3RA) is administered in the form of a pharmaceutical composition comprising:
 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide (NK3RA); 
 mannitol and microcrystalline cellulose; 
 croscarmellose sodium, 
 hydroxypropyl cellulose, 
 sodium lauryl sulphate, and 
 magnesium stearate.